julie gralow, md, discusses outcomes from the tailorx study presented at asco 2018
Published 6 years ago • 84 plays • Length 1:50
Download video MP4
Download video MP3
Similar videos
-
0:50
julie gralow, md, discusses the outcomes of the paloma-2 study presented at asco 2016
-
2:27
julie gralow, md, reflects on the persephone trial from the 2018 asco annual meeting
-
0:50
julie gralow, md, discusses the monarch 1 study
-
0:37
julie gralow, md, comments on the practice-changing implications of the tailorx study
-
0:52
julie gralow, md, tells us about the sandpiper proof of concept trial presented at acso 2018
-
0:32
julie gralow, md, on the implications of the persephone trial in early her2 breast cancer
-
16:11
dr. julie r. gralow discusses findings from the rxponder study released at sabcs 2020
-
2:35
julie gralow, md, elaborates on the issue of resistance to endocrine therapies
-
2:01
julie gralow, md, on the kristine study
-
3:34
julie gralow, md, provides details on the swog s0226 findings presented at sabcs 2020
-
1:03
ana aparicio, md, explains data and conclusions from her presentation at asco gu 2017
-
0:44
julie gralow, md, regarding the reduction in cardiac events in the persephone study
-
1:01
douglas w. blayney, md, discusses the biggest takeaway regarding breast cancer here at asco 2018
-
1:40
julie gralow, md, elaborates on how to differentiate cdk4/6 inhibitors
-
1:14
julie gralow, md, shares her thoughts on new drugs in development for breast cancer.
-
0:21
julie vose, md, discusses whether polatuzumab improves outcomes in dlbcl patients
-
0:37
julie vose, md, tells us about results of the augment study in relapsed/refractory indolent nhl
-
0:49
julie vose, md, on if car-t therapies are showing impressive results in lymphoma
-
10:31
julie r. gralow, md: the atlas trial. tamoxifen for five years or ten years?
Clip.africa.com - Privacy-policy